Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
The objective of this report is to provide recommendations for the optimal management of warfarin for the prevention of thromboembolic events in patients with atrial fibrillation (AF). Three specific questions were asked to CADTH COMPUS Expert Review Committee (CERC) members:
- Question 1: What is the role of specialized anticoagulation services or other anticoagulation management options for the optimal management of warfarin therapy?
- Question 2: What is the role of patient self-testing and patient self-management for the optimal management of warfarin therapy?
- Question 3: In remote areas, what types of anticoagulation management options can be recommended?
Contents
- 1. INTRODUCTION
- 2. ISSUE
- 3. OBJECTIVE
- 4. PROJECT OVERVIEW
- 5. RESULTS
- 6. THE EVIDENCE
- 7. CONSIDERATION OF THE EVIDENCE
- 8. NEXT STEPS
- APPENDIX A EXPERT COMMITTEE AND CONTRIBUTORS
- APPENDIX B COMPUS EXPERT REVIEW COMMITTEE DELIBERATION PROCESS AND INTERPRETATION OF FINDINGS
- APPENDIX C COMPUS EXPERT REVIEW COMMITTEE VOTING PROCESS
- APPENDIX D ABBREVIATIONS
- REFERENCES
This report is prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). This report contains a review of existing public literature, studies, materials, and other information and documentation (collectively the “source documentation”) available to CADTH at the time it was prepared, and it was guided by expert input and advice throughout its preparation.
The information in this report is intended to help health care decision-makers, patients, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgment in respect to the care of a particular patient or other professional judgment in any decision-making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of this report to ensure that its contents are accurate, complete, and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this report.
CADTH takes sole responsibility for the final form and content of this report. The statements, conclusions, and views expressed herein do not necessarily represent the view of Health Canada or any provincial or territorial government.
Production of this report is made possible through a financial contribution from Health Canada.
- Optimal Warfarin Management for Prevention of Thromboembolic Events in Patients with Atrial Fibrillation
- Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence
- Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: Review of Canadian Economic Studies
- Warfarin Management in Patients with Atrial Fibrillation — Current Practice Study
- NLM CatalogRelated NLM Catalog Entries
- Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.[Circulation. 2014]Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, Gallinghouse GJ, Themistoclakis S, Rossillo A, Lakkireddy D, et al. Circulation. 2014 Jun 24; 129(25):2638-44. Epub 2014 Apr 17.
- Review Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence[ 2011]Review Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence. 2011 Nov
- Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.[Am J Cardiol. 2013]Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.Atay JK, Fanikos J, Barnes GD, Ehle M, Coatney J, Piazza G, Froehlich JB, Goldhaber SZ. Am J Cardiol. 2013 Aug 1; 112(3):387-9. Epub 2013 May 3.
- Review Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls.[Ann Pharmacother. 2008]Review Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls.Garwood CL, Corbett TL. Ann Pharmacother. 2008 Apr; 42(4):523-32. Epub 2008 Mar 11.
- Review Prevention of stroke in patients with atrial fibrillation.[Semin Vasc Med. 2005]Review Prevention of stroke in patients with atrial fibrillation.Olsson SB, Halperin JL. Semin Vasc Med. 2005 Aug; 5(3):285-92.
- Recommendations for Optimal Warfarin Management for Prevention of Thromboembolic...Recommendations for Optimal Warfarin Management for Prevention of Thromboembolic Events in Patients with Atrial Fibrillation
- 10564707[uid] (1)PubChem Compound
Your browsing activity is empty.
Activity recording is turned off.
See more...